Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus
| Autor: | Ronald L. Prigeon, Julie A. Predhomme, Anh Vu, Christina L. Aquilante, Kimberly M. Deininger, Maha S. Sidhom, Lisa A. Kosmiski, Brooke C Bredbeck, Amber L. Beitelshees |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Administration Oral 030209 endocrinology & metabolism Blood Pressure 030204 cardiovascular system & hematology Placebo GPI-Linked Proteins 03 medical and health sciences 0302 clinical medicine Double-Blind Method Diabetes mellitus Internal medicine Lectins medicine Humans Hypoglycemic Agents Pharmacology (medical) Prospective Studies Prospective cohort study Metabolic Syndrome Adiponectin Dose-Response Relationship Drug Pioglitazone business.industry Body Weight Middle Aged medicine.disease Lipids Blood pressure Endocrinology Treatment Outcome Pharmacodynamics Cytokines Female Thiazolidinediones Metabolic syndrome Waist Circumference business medicine.drug |
| Zdroj: | Pharmacotherapy. 36(3) |
| ISSN: | 1875-9114 |
| Popis: | Study Objective To determine the effects of low-dose pioglitazone on plasma adipocyte-derived cytokines, high-sensitivity C-reactive protein (hs-CRP), and components of the metabolic syndrome in adults with the metabolic syndrome without diabetes mellitus. Design Prospective, randomized, double-blind, placebo-controlled study. Setting University of Colorado Clinical and Translational Research Center. Patients Thirty-two men and women, aged 30–60 years, without diabetes who had a clinical diagnosis of the metabolic syndrome, as defined by the American Heart Association/National Heart, Lung, and Blood Institute criteria. Intervention Patients were randomly assigned to receive oral pioglitazone 7.5 mg daily or matching placebo for 8 weeks. Measurements and Main Results The primary end point was the change in plasma high-molecular-weight (HMW) adiponectin level from baseline to week 8. Other end points were changes in plasma total adiponectin, omentin, and hs-CRP levels, and changes in components of the metabolic syndrome (e.g., insulin sensitivity) from baseline to week 8. Pioglitazone was associated with a significant increase in plasma HMW adiponectin from baseline to week 8 compared with placebo (+47% vs −10%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text